SCHEMBL1676828

SCHEMBL1676828

COC(=O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2-c2ccc(OCc3ccc(S(C)(=O)=O)cc3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
PTGS2 P35354 1/20 0.43
BCL2L1 Q07817 1/20 0.43
MCL1 Q07820 1/20 0.43
LMNA P02545 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
CNR1 P21554 3/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
DRD2 P14416 1/20 0.40
TBXA2R P21731 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676153 0.92 PTGS2 (0.45) NPC1RAB9APTGS2BCL2L1MCL1
SCHEMBL1481092 0.86 NPC1 (0.42) NPC1RAB9ACNR1KDM4EALDH1A1
SCHEMBL1679409 0.86 NPC1 (0.41) NPC1RAB9APTGS2BCL2L1MCL1
SCHEMBL1481331 0.86 NPC1 (0.46) NPC1RAB9ACNR1DRD2TBXA2R
SCHEMBL1676348 0.86 NPC1 (0.55) NPC1RAB9ACNR1DRD2TBXA2R
SCHEMBL1480783 0.86 DRD2 (0.43) NPC1RAB9APTGS2DRD2TBXA2R
SCHEMBL1676555 0.85 DRD2 (0.47) NPC1RAB9APTGS2CNR1DRD2
SCHEMBL1481936 0.84 DRD2 (0.46) NPC1RAB9APTGS2CNR1DRD2
SCHEMBL1676347 0.84 PTGS2 (0.39) NPC1RAB9APTGS2KDM4EALDH1A1
SCHEMBL1481489 0.83 CA12 (0.43) NPC1RAB9APTGS2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE NPC1 3228/4885RAB9A 3396/4885PTGS2 1321/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE NPC1 3228/4885RAB9A 3396/4885PTGS2 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.